Lilly outperforms Novo in oral GLP-1 market (LLY:NYSE)
· seekingalpha.com
Eli Lilly’s (LLY) oral GLP-1 therapy, Foundayo, beats Q2 2026 sales estimates, heating up rivalry with Novo’s (NVO) Wegovy pill. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...